Implants
Deep access, with an invasive procedure.
Non-invasive neuromodulation
Breaking the barrier
to the brain.
Focused ultrasound. Smartphone guidance.
A new approach to neuromodulation, in development.
Research in progress
DeepBrain is developing a non-invasive focused-ultrasound headset and smartphone companion for future clinician-supervised use. It is not available to buy. Clinical performance figures are design targets pending clinical confirmation.
Scroll to discover
Research and advisory network
University of Nottingham
University of Strathclyde
University of Cambridge
01 / The access challenge
Making brain stimulation more accessible.
Implanted deep brain stimulation already exists and requires surgery. Different stimulation approaches have different targeting and supervision requirements. DeepBrain is exploring a non-invasive approach intended for future clinician-supervised use.
- 01
Non-invasive access. Explore brain stimulation without an implanted device.
- 02
Targeting precision. Evaluate the accuracy of smartphone-guided placement and focused ultrasound.
- 03
Clinical evidence. Establish safety and outcomes before any proposed treatment use.
02 / The science of precision
Precision targeting in development,
guided by a phone.
The proposed system combines focused ultrasound with smartphone-guided placement. The intended closed loop would use biosignals to inform dose adjustments. Targeting accuracy, safety and clinical outcomes need evaluation.
Precision, beneath the surface01 — 03
Three connected design questions: where to place, where to focus and how to adapt.
-
01
Precise placement
The proposed phone guidance would support headset placement. Accurate targeting without MRI is a design aim that needs validation.
-
02
Reach the right target
The design explores targeting deeper regions such as the thalamus and amygdala. The atlas illustrates that intent, rather than proven device performance.
-
03
Adapt with AI
The intended closed loop would use EEG and HRV to inform dose adjustments. Its performance and clinical value need evaluation.
The interactive atlas
Explore what
lies beneath.
Explore three target regions in the brain. Rotate the model, choose a target and see how the illustrative focal depth changes.
An interactive explanation of the design intent. This is not a treatment simulator or a clinical scan.
Select a region to explore
Target · ThalamusInteractive anatomy
Drag to rotate. Use the controls to zoom or reset.
Focal depth
~55 mm
Focal energy
0.46 W/cm²
Approach
Non-invasive
Mode
Closed loop
Stimulation intensity
55% · Moderate
Compare the illustrative focal response. These are not treatment settings.
Design targets, dose-limited. Pending clinical confirmation.
The companion experience
From placement
to perspective.
A proposed companion for each stage of a session. Guidance on your phone, with your clinician in the loop.
Placement
A clear starting point.
The phone is designed to guide headset placement, helping bring the focal point towards the intended target.
AligningIllustration
Horizontal+4.2 mm
Vertical−2.8 mm
Tilt1.6°
The values illustrate the interface. They are not measurements from a connected headset.
An illustrative session
04:12
of 10 minutes
Thalamus~55 mm focal depth
The session
Know where you are.
Time, target and dose belong in one clear view. The companion is designed to keep the session understandable while the system manages its limits.
- Approach
- Non-invasive
- Dose control
- Within a set ceiling
- Oversight
- Clinician supervised
Illustrative session. Duration, targeting and dose are design intent, pending clinical confirmation.
Signal studyIllustrative trace
EEG Electrical activity
HRV Heart-rate variability
Generated demonstration signals · No live recording
Monitoring
A session that listens.
The proposed closed loop reads EEG and HRV during a session, using biosignals to inform dose adjustments within defined limits.
62 bpmIllustrative heart rate
These traces explain the intended interaction. They do not indicate a person's focus, health or response to treatment.
Session historyIllustrative month
12sessions
this month
this month
01020304050607080910111213141516171819202122232425262728
Session recorded
Review
The longer view.
A history of sessions gives you and your clinician a place to review consistency, adherence and safety limits over time.
94%Illustrative adherence
Example data only. Session counts and adherence do not demonstrate treatment effectiveness.
Companion concept · In development. No medical advice or live device connection.
04 Comparison
Three ambitions.
One approach.
Deep targeting. Use beyond the clinic. Adaptation to the individual. DeepBrain is designed to bring them together.
DeepBrain’s design intent
Bring precision
closer to daily life.
Each approach makes different trade-offs. Our aim is to combine deep targeting with non-invasive use and personalisation.
Clinic systems
Targeted stimulation in a clinical setting.
Consumer wearables
Convenience at home, with limits on deep targeting.
Compare the five capabilities
| Capability | Implants | Clinic systems | Consumer wearables | DeepBrain |
|---|---|---|---|---|
| Non-invasive | No | Yes | Yes | Yes |
| Reaches deeper targets | Yes | Yes | No | Yes |
| Designed for home use | No | No | Yes | Yes |
| No MRI required | n/a | No | Yes | Yes |
| AI personalisation | Limited | Limited | No | Yes |
Comparison reflects DeepBrain’s design intent versus typical alternatives. All performance figures are design targets pending clinical confirmation.
05 Safety
Safety is part of the design.
Home use has to be safe by default, so these controls are part of the design from the start.
-
DOSE
Dose ceilings
The design proposes limits on intensity and duration. Appropriate session schedules and dose limits need clinical evaluation.
-
SIGNAL
Live monitoring
The intended monitoring system would flag readings outside expected ranges. Its reliability and response rules need testing.
-
OVERSIGHT
Clinician oversight
Future home use would require appropriate clinical supervision and a tested monitoring workflow.
-
ACCESS
Secure by default
Device integrity and access controls are development requirements. Security controls need evaluation before deployment.
The next chapter is clinical evidence.Conceptual illustration
06 Roadmap
From the lab to the living room.
Current work
Prototype evaluation
Prototype development and planned feasibility studies. Published clinical outcome evidence for the proposed device is not available on this site.
Next evidence milestone
Clinical pilot
Structured clinician interviews and a clinical pilot, with safety, monitoring and the regulatory pathway toward UKCA and CE marking.
Longer-term ambition
Supervised home use
Future ambition: supervised home programmes, subject to clinical evidence, safety evaluation and the applicable regulatory pathway.
07 Team
Who is building DeepBrain.
Neuromodulation, brain-network science, biomedical engineering, AI and commercial execution, in one team.
-
Om RoyCEO · AI and neuromodulationUniversity of Strathclyde -
Prof. Marcus KaiserCSO · Brain networksUniversity of Nottingham -
Dr. Keith SmithBiomedical LeadUniversity of Strathclyde -
Dr. Yashar MoshfeghiAI LeadUniversity of Strathclyde -
Alex ChristouBusiness DevelopmentUniversity of Strathclyde
Advisory board
- Peter SchlechtVenture capital
- Prof. Feng HaoCambridge · Security engineering
- Paul CableCEO · NeuPulse
- Jon HackerCEO · NeurGear
- Dave HughesCEO · Halya
08 Questions
Common questions.
Is DeepBrain a medical device I can buy today?
No. DeepBrain is a pre-launch development project. The proposed headset and companion app are not available to buy. Clinical effectiveness, safety and regulatory requirements need evaluation before treatment or home use.
How is this different from a consumer wellness wearable?
DeepBrain is exploring focused ultrasound, smartphone-guided placement and adaptive monitoring. The aim is future clinician-supervised use beyond the clinic. These are development goals, not demonstrated advantages over every other device.
Does it require surgery or an MRI?
The proposed approach is non-invasive and aims to use smartphone-guided placement without MRI. These are design goals whose accuracy and safety still need evaluation.
How do you keep home use safe?
The design proposes session limits, dose ceilings, biosignal monitoring and clinician oversight. These safeguards need testing and clinical evaluation. This website does not offer treatment or individual dosing advice.
Who is behind DeepBrain?
A team spanning neuromodulation, brain-network science, biomedical engineering, AI and commercial execution, drawn from the Universities of Nottingham and Strathclyde, with an advisory board across venture capital, security engineering and neurotech.
Follow the research.
Join the waitlist for development updates, pilot opportunities and early access as DeepBrain moves from the lab toward the home.
We only use your email for waitlist updates. Privacy Policy